We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Investors will want to consider Coca-Cola’s stock as the company approaches its first-quarter earnings report. Edging closer to its 52-week highs the beverage giant currently sports a Zacks Rank #2 (Buy) with its Beverage-Soft Drink Industry in the top 19% of over 250 Zacks industries.
Q1 Preview: Coca-Cola’s Q1 earnings are expected to be up 1% from the prior year quarter at $0.65 per share. First-quarter sales are forecasted to rise 3% year over year at $10.87 billion. Plus, earnings estimate revisions have slightly gone up over the last quarter.
The bottom line growth of Coca-Cola is still steady with earnings now expected to rise 5% this year and jump another 7% in FY24 at $2.79 per share. Total sales are forecasted to be up 4% this year and rise another 5% in FY24 to $47.16 billion.
Also standing out before its Q1 earnings is Cadence Design Systems with a Zacks Rank #2 (Buy) and the Computer-Software Industry in the top 39% of all Zacks industries.
Providing tools that help customers design electronic products, Cadence''s offerings appear to be in higher demand. Cadence offers software, hardware, services and reusable IC design blocks (IPs) to electronic systems and semiconductor customers.
Q1 Preview: First-quarter earnings are projected to be up 7% YoY at $1.25 per share with sales forecasted to rise 11% to $1.01 billion. Notably and very impressive, Cadence has beaten earnings expectations for 22 consecutive quarters and topped sales estimates in its last 24 quarterly reports.
Even better, annual earnings are anticipated to jump 16% this year and pop another 7% in FY24 at $5.34 per share. Earnings estimate revisions have noticeably gone up, rising 9% for FY23 over the last 90 days and up 6% for FY24.
Lastly, Chugai Pharmaceuticals sports a Zacks Rank #2 (Buy) and is a lesser-known name that investors should pay attention to. Chugai’s Medical-Drug Industry is also in the top 39% of Zacks industries.
The Tokyo-based company’s first-quarter earnings could help confirm its stellar earnings growth. Chugai appears to be building a necessary niche in the healthcare field as a provider of pharmaceutical products for kidney diseases, kidney transplantation, bone and joint diseases, and cancer treatment.
Q1 Preview: Impressively, Chugai’s Q1 earnings are forecasted to climb 100% YoY at $0.68 per share compared to EPS of $0.34 in the prior year quarter. This is even more impressive considering sales are projected to decline -29% at $2.20 billion compared to $3.10 billion in Q1 2022.
Still, Chugai’s bottom line is very intriguing as annual earnings are now projected to soar 226% this year at $2.84 per share Vs. EPS of $0.87 in 2022. Fiscal 2024 earnings are expected to be virtually flat but slightly up at 2.85 per share.
Image Source: Zacks Investment Research
Takeaway
The annual EPS growth for these companies is hard to overlook going into their Q1 reports. To that point, first quarter results could start to reaffirm this and lead to more upside in their stocks. Given their anticipated bottom-line expansion, Coca-Cola, Cadence Design Systems, and Chugai Pharmaceuticals are starting to look like sound investments for 2023 and beyond.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
3 Stocks to Consider with Earnings Approaching
As we progress through earnings season several top-rated Zacks stocks are expected to report their first quarter results on Monday, April 24.
Let’s take a look at three of these stocks that investors may want to consider buying with their earnings reports upon us.
Coca-Cola (KO - Free Report) )
Investors will want to consider Coca-Cola’s stock as the company approaches its first-quarter earnings report. Edging closer to its 52-week highs the beverage giant currently sports a Zacks Rank #2 (Buy) with its Beverage-Soft Drink Industry in the top 19% of over 250 Zacks industries.
Q1 Preview: Coca-Cola’s Q1 earnings are expected to be up 1% from the prior year quarter at $0.65 per share. First-quarter sales are forecasted to rise 3% year over year at $10.87 billion. Plus, earnings estimate revisions have slightly gone up over the last quarter.
The bottom line growth of Coca-Cola is still steady with earnings now expected to rise 5% this year and jump another 7% in FY24 at $2.79 per share. Total sales are forecasted to be up 4% this year and rise another 5% in FY24 to $47.16 billion.
Image Source: Zacks Investment Research
Cadence Design Systems (CDNS - Free Report) )
Also standing out before its Q1 earnings is Cadence Design Systems with a Zacks Rank #2 (Buy) and the Computer-Software Industry in the top 39% of all Zacks industries.
Providing tools that help customers design electronic products, Cadence''s offerings appear to be in higher demand. Cadence offers software, hardware, services and reusable IC design blocks (IPs) to electronic systems and semiconductor customers.
Q1 Preview: First-quarter earnings are projected to be up 7% YoY at $1.25 per share with sales forecasted to rise 11% to $1.01 billion. Notably and very impressive, Cadence has beaten earnings expectations for 22 consecutive quarters and topped sales estimates in its last 24 quarterly reports.
Even better, annual earnings are anticipated to jump 16% this year and pop another 7% in FY24 at $5.34 per share. Earnings estimate revisions have noticeably gone up, rising 9% for FY23 over the last 90 days and up 6% for FY24.
Image Source: Zacks Investment Research
Chugai Pharmaceuticals (CHGCY - Free Report) )
Lastly, Chugai Pharmaceuticals sports a Zacks Rank #2 (Buy) and is a lesser-known name that investors should pay attention to. Chugai’s Medical-Drug Industry is also in the top 39% of Zacks industries.
The Tokyo-based company’s first-quarter earnings could help confirm its stellar earnings growth. Chugai appears to be building a necessary niche in the healthcare field as a provider of pharmaceutical products for kidney diseases, kidney transplantation, bone and joint diseases, and cancer treatment.
Q1 Preview: Impressively, Chugai’s Q1 earnings are forecasted to climb 100% YoY at $0.68 per share compared to EPS of $0.34 in the prior year quarter. This is even more impressive considering sales are projected to decline -29% at $2.20 billion compared to $3.10 billion in Q1 2022.
Still, Chugai’s bottom line is very intriguing as annual earnings are now projected to soar 226% this year at $2.84 per share Vs. EPS of $0.87 in 2022. Fiscal 2024 earnings are expected to be virtually flat but slightly up at 2.85 per share.
Image Source: Zacks Investment Research
Takeaway
The annual EPS growth for these companies is hard to overlook going into their Q1 reports. To that point, first quarter results could start to reaffirm this and lead to more upside in their stocks. Given their anticipated bottom-line expansion, Coca-Cola, Cadence Design Systems, and Chugai Pharmaceuticals are starting to look like sound investments for 2023 and beyond.